Real-world evidence is more than just another way of tracking post-market patterns in drug utilization, said Maria Koehler, vice president of oncology strategy, innovation and collaborations at Pfizer Oncology.
As the debate around Galleri, the multi-cancer detection test developed by GRAIL Inc., rages on, fueled most recently by the full-steam-ahead support it has received from regulatory and legislative bodies, NCI Director Anthony Letai has turned his attention to the available data.
